[1]赵华婷,颜建周,邵 蓉.典型国家疗效协议研究及启示[J].卫生经济研究,2020,(04):51-53.
　ZHAO Hua-ting,YAN Jian-zhou,SHAO Rong.Study and Inspiration of Efficacy Agreements in Typical Countries[J].Journal Press of Health Economics Research,2020,(04):51-53.
点击复制

典型国家疗效协议研究及启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2020年04期
页码:
51-53
栏目:
药械管理
出版日期:
2020-04-02

文章信息/Info

Title:
Study and Inspiration of Efficacy Agreements in Typical Countries
作者:
赵华婷1; 颜建周1; 邵 蓉1
1.中国药科大学国家药物政策与医药产业经济研究中心，江苏 南京 211198
Author(s):
ZHAO Hua-ting; YAN Jian-zhou; SHAO Rong
National Pharmaceutical Policy and Pharmaceutical Industry Economic Research Center，China Pharmaceutical University，Nanjing Jiangsu 211198，China
关键词:
医保; 药品谈判; 疗效协议; 风险共担
Keywords:
medical insurance; drug negotiation; efficacy agreement; risk sharing
分类号:
F840.684
文献标志码:
A
摘要:
基于我国医保药品谈判的现状与存在问题，主要研究了典型发达国家的药品疗效协议，包括基本含义、协议品种、协议内容（观察指标与周期、数据收集、响应与支付），在此基础上，提出建议：提高我国医保药品谈判的全面性与科学性、建立专业的评估体系与机构。
Abstract:
Based on the status quo and existing problems of China's medical insurance drug negotiations，the drug efficacy agreements in typical developed countries are studied，including the basic meaning，the types of agreements，and the content of the agreements (observation indicators and cycles，data collection，response and payment). This paper put forward suggestions to improve the comprehensiveness and scientificity of China's medical insurance drug negotiations and establishment of a professional evaluation system and institutions.

参考文献/References:

[1] 人民网. 国家谈判促药价腰斩 肺癌乙肝三种药品最高降67％[EB/OL].（2016-05-21）.http://bj.people.com.cn/n2/2016/0521/c233081-28375871.html.
[2] 健康界. 人社部公布44种药品谈判结果 36种药品谈判成功[EB/OL]. （2017-07-19）.https://www.cn-healthcare.com/article/20170719/content-494165.html.
[3] 中国医疗保险. 一目了然 2018医保抗癌药谈判降价幅度[EB/OL]. （2018-10-10）.https://www.cn-healthcare.com/articlewm/20181010/content-1035680.html.
[4] 董朝晖.如何建立药品谈判机制[J].中国社会保障,2015(7):74-77.
[5] 刘伟,管晓东,李虹耀,等.国外医疗保险药品谈判结果实施模式研究进展[J].中国药事,2016,30(1):1-7.
[6] Kuchenreuther，Michael J. Abrams Michael N. Risk-Sharing Agreements in the EU and Considerations for Moving Forward[J]．Pharmaceutical Technology Europe，2015，27 (11):10-13.
[7] Haitham W.Tuffaha.Paul A.Scuffam.The Australian Managed Entry Scheme：Are We Getting it Right?
[8] francisco R Goncalves,Susana Santos,Catarina Silva,Gabriela Sousa.Risk-sharing agreements,present and future[J].Ecancermedicalscience,2018,12:823.
[9] 常峰，崔鹏磊，张舰云，等.全球视角下药品风险分担协议政策分析[J].卫生经济研究,2016 （8）:39-44.

相似文献/References:

[1]潘春燕.DRG支付方式的实践探讨——以JH市试点情况为例[J].卫生经济研究,2019,(08):38.
　PAN Chun-yan.Discussion on the Practice of DRG Payment Method——Taking the Pilot of JH City as an example[J].Journal Press of Health Economics Research,2019,(04):38.

更新日期/Last Update: 2020-04-02